Thymalin and Vilon are the thymic pair of the bioregulator group, and they are different kinds of object. Vilon is a dipeptide with a defined sequence, a calculable mass and a certificate that looks like any other peptide's. Thymalin is an extract-derived preparation, a mixture rather than a molecule, and the questions a certificate can answer about it are different. Reading the two together is the clearest way to see what "bioregulator" does and does not tell you.
Where they come from
The programme that produced the bioregulator group began with extracts. Tissue — here, calf thymus — was processed to a peptide fraction and that fraction was studied as a preparation. Thymalin is that preparation, developed in the 1970s and 80s and used in the source country's clinical practice since. It is a mixture of short peptides whose exact composition varies with the source tissue and the process, which is why it has a name but not a sequence.
Vilon came later, by the programme's second method: find a short sequence recurring in the extract, synthesise it, and study the defined molecule. Lys-Glu — two residues, the shortest thing in the catalogue — was proposed as an active principle of the thymic fraction and became a compound in its own right.
| Thymalin | Vilon | |
|---|---|---|
| Nature | Extract-derived preparation | Synthetic dipeptide |
| Sequence | Not a single sequence | Lys-Glu |
| Mass | A distribution | 275 Da |
| Identity on a certificate | Process and profile | One observed mass |
| Lot-to-lot variation | Inherent | Ordinary synthesis variation |
What can a certificate say about a preparation with no single sequence?
Less than for a defined peptide, and what it says is different in kind. There is no theoretical mass to match, so identity cannot be a single number; it becomes a profile — a chromatographic fingerprint, a mass distribution, a peptide content by nitrogen — compared against a reference batch. Purity has no clean meaning when the material is a mixture by design. What can be reported honestly is process consistency, total peptide content, and the safety panels that apply to anything: endotoxin, residual solvent, microbial limits. Reading each panel for what it proves matters here in an unusual way: the panels that are absent are absent because they cannot exist, not because they were skipped.
Is a two-residue peptide really a peptide?
Chemically, yes — one peptide bond joins two amino acids, which is the definition. Practically, Vilon behaves more like a small polar molecule than like anything else in the catalogue. It has no structure to lose, it is highly soluble, it carries one positive and two negative charges at neutral pH, and it is cleared and cleaved within minutes of meeting a peptidase. The conventions that separate peptides from proteins place it firmly at the bottom of the peptide range, and everything about handling it follows from that.
What the literature claims, and how to read it
Both are associated in the source literature with immune modulation and, in the programme's framing, with restoring thymic function in aged systems. The same reading discipline applies as to the rest of the group: much of the primary work is in Russian-language journals with limited indexing, concentrated in a small number of connected groups, and less independently replicated than its citation count implies.
Thymalin carries one thing the synthetic bioregulators do not: decades of clinical use in one country under its own regulatory system. That is a real evidence base and it is also a different one — observational and practice-based rather than the controlled, independently replicated work that would establish mechanism. It should be weighted as what it is.
Is Vilon the "active ingredient" of Thymalin?
That is the programme's proposal, and it is the claim to hold most carefully. Identifying a recurring dipeptide in an extract and showing the dipeptide has effects of its own does not establish that the dipeptide accounts for the extract's effects. A mixture may act through several components, through none of them individually, or through something the analysis did not resolve. Vilon may well be active; whether it is Thymalin's activity is a separate question that the literature does not settle. The two are catalogued separately for that reason, and studying one is not studying the other.
How do the two handle in the laboratory?
Vilon as the simplest case in the catalogue: water-soluble, no cysteine, no oxidisable residues, stable dry, and destroyed within minutes by any medium containing aminopeptidases — make it fresh, use it promptly. Its exposure is not chemistry but surfaces: a 275-dalton peptide at working concentration loses a large fraction of itself to a tube wall.
Thymalin as a mixture: soluble, but with components that may differ in solubility and stability, so a solution should be treated as having the shelf life of its most fragile part. Endotoxin deserves particular attention, since a tissue-derived preparation studied for immune effects is exactly the case where a contaminant produces the result being looked for.
What should a write-up record for these two specifically?
For Vilon, the sequence — because the name means nothing outside the field — plus lot, content and the usual. For Thymalin, the lot above all, since the preparation varies by batch in a way a synthetic peptide does not, and the certificate's profile is the only description of what was used. A result with Thymalin that does not cite a lot cannot be repeated even in principle. That is the practical cost of working with a preparation rather than a molecule, and it is worth knowing before choosing to.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
